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A retrospective multicentric study was performed from a one-
year (2005) registry of patients from ﬁve primary care centres in
Spain. Inclusion criteria were as follows: mild to moderate HT
as per JNC-VII, British Hipertensión-Society; and DL as per
NCEP-ATP III. Compliance was estimated by the relationship
between the amount of dispensed and prescribed pills. Demo-
graphic variables, comorbidities, clinical parameters and sanitary
resources were registered. A bivariant analysis and a multiple
lineal regression analysis were done to correct the model.
RESULTS: Compliance was estimated from the total sample of
15,606 patients (HT: 41.7%; DL: 23.1%; HT/DL: 35.2%), in
85.9% (CI = 85.4–86.4%), 81.6% (CI = 81.0–82.2%) and
84.9% (CI = 84.3–85.5%) respectively (p = 0.000; Scheffé).
Explanatory variables of a better compliance in the multivariate
analysis were (beta = 0.832; t = 59.1; p = 0.000): a) direct rela-
tionship: age, labour inactivity, drug price, and b) indirect rela-
tionship: glycemia, triglycerides, LDL and number of active
principles used (p = 0.000). CONCLUSION: Dyslipidemic
patients show a worse compliance than hypertensive patients,
and dyslipidemia worsened global compliance in hypertensive
patients. Certain clinical parameters of control, the age of the
patient and the drug group are related to compliance in daily
medical practice.
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OBJECTIVES: Therapeutic compliance (TC) is related to risk
control in the hypertensive patient. Nevertheless there is no much
information on how the improvement of TC impacts on cardio-
vascular risk factors (CVRF), particularly on lipid parameters,
in the Spanish hypertensive patients. To analyze the relationship
among TC improvement (estimated by the relationship between
amount of drug dispensed and amount of drug prescribed), and
the variations in LDL-cholesterol (LDLc) and HDL-cholesterol
(HDL-c) levels. METHODS: Hypertensive patients from ﬁve
Spanish primary care centres, who had registered values of LDLc
and HDLc, between 2004 and 2005, were retrospectively
studied. Changes in TC, LDLc and HDLc were calculated
between mentioned years. Correlation between: a) changes in TC
and HDL, and b) changes in TC and HDL, were calculated using
the Spearman’s Rho test. RESULTS: Of the 6960 hypertensive
patients, 5094 had registered HDL-c levels in 2004 and 2005.
An increase in TC of 3.8% (DE:17.7%) was demonstrated. An
inverse and statistically signiﬁcant relationship between LDLc
and TC (p = 0.003) was demonstrated. No relationship was
found between TC improvement and HDLc (p = 0.9456) CON-
CLUSIONS: In the Spanish hypertensive population, CT
improvements are associated to a decrease in LDLc levels, with
no impact on HDL. Available treatments are not effective enough
to improve HDLc levels in the Spanish hypertensive patient.
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OBJECTIVE: Blood pressure control can be difﬁcult to achieve
in hypertension, often requiring combination pharmacotherapy.
A variety of approaches are available, including ﬁxed dose com-
binations (FDC) versus individual components (IC). The purpose
of this analysis was to assess combination valsartan and hydro-
cholorthiazide (HCTZ) therapy in previously antihypertensive
naïve patients. METHODS: A national database of insured
patients ages 18 & older with hypertension were evaluated for
combination valsartan and HCTZ use initiated within 180 days
of each other. Patients had at least two claims for this combina-
tion of pharmacotherapy within one year of their ﬁrst prescrip-
tion. Eligibility included continuous enrollment 110 days prior
to ﬁrst prescription and 365 days following dual therapy. Eligi-
ble patients were antihypertensive naïve 110 days prior to study
drug initiation. Combination pharmacotherapy persistency at
365 days was calculated and sensitivity analysis was performed
for the length of reﬁll gaps. RESULTS: There were 2,022,578
unique patients age18 years or older identiﬁed with hypertension
ICD-9 codes (401.0, 401.1, 401.9, 402.1 & 402.9). After apply-
ing study criteria there were 8711 eligible patients; 8150 FDC
and 561 IC. In assessing ongoing persistence, patients could not
have a reﬁll gap in excess of 120% of previous prescription day’s
supply. FDC persistency was 54% (4362/8150) compared to
19% (109/561) for IC at 365 days (p < 0.0001). Using a more
stringent threshold (80% days supply), FDC was 44%
(3623/8150) vs. IC 16% (91/561) p < 0.0001. Increasing the
threshold (160% days supply) the FDC was 59% (4821/8150)
vs. IC 21% (119/561) p < 0.0001. CONCLUSIONS: Use of FDC
is more common (93.5%) than individual components for this
previously naïve antihypertensive population. The ﬁxed dose
combination therapy group was shown to have signiﬁcantly
better persistence at 365 days vs. the individual components
group, which proved to be quite robust following a sensitivity
analysis.
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Reduction of cardiovascular risk frequently requires the 
co-administration of multiple antihypertensive (AH) and lipid
lowering (LL) drugs. Fixed combinations of two drugs could
improve daily compliance by simplifying the treatment regimen.
OBJECTIVE: To assess which antihypertensive patients might
beneﬁt from a combination of AH and LL drugs. METHODS:
Hypertensive patients (>=30 years plus >=3 cardiovascular risk
factors or events (CVD), experienced or new users of antihyper-
tensive drugs between June 2003-June 2004)were selected from
the IPCI database in The Netherlands. A written questionnaire
was administered in October 2005 regarding reasons for non-
compliance, likelihood of missing a dose if two pills would be
combined in one, and self-reported medication-taking. Percent-
age of days covered (PDC) with AH medication was calculated
from the prescription records. RESULTS: A total of 729 out of
1473 patients responded, 101 were new users of antihyperten-
sive drugs, 349 had CVD. Respondents (75% male, median age
63 years) used on average 3 drugs, and 40% used LL drugs at
start of follow-up. Side effects, lack of efﬁcacy, and forgetting
